BioMarin Pharmaceutical (NASDAQ: BMRN) logged over $1 billion in revenue — the traditional level for a blockbuster — for the first time in 2016. Of course, that’s combined sales of its four drugs, but it’s still a mighty accomplishment that many drugmakers never reach.
Metric
Q4 2016